Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

David Bing Zhen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3375-5912; OpenAlex author ID A5091106115. Sources: ClinicalTrials.gov.

Their work

Papers
11 (first author 2, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 1 trial · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 11

  1. Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinom… Co-author DOI 10.3390/cancers18030507↗
  2. The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and … Co-author DOI 10.1016/j.jgo.2023.101474↗
  3. Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002253↗
  4. The role of molecular testing in pancreatic cancer. Co-author DOI 10.1177/17562848231171456↗
  5. Combination immunotherapy for pancreatic cancer: challenges and future considerations. First author DOI 10.1080/1744666x.2022.2120471↗
  6. DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001819↗
  7. Ultra-low Input Circulating Tumor DNA Detection by MED-Amp in Early-Stage Pancreatic Cancer First author DOI 10.1101/2021.03.28.437388↗
  8. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma. Co-author DOI 10.1053/j.seminoncol.2018.05.004↗
  9. A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. Co-author DOI 10.1007/s10637-016-0376-1↗
  10. Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson. Co-author DOI 10.1200/jco.2015.63.3511↗
  11. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Co-author DOI 10.1038/gim.2014.153↗

Trials 1

  1. Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors Principal investigator NCT03891784↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elena Gabriela Chiorean · 6 shared papers, 2018–2026 · strength 1.06
  2. Andrew L. Coveler · 4 shared papers, 2018–2026 · strength 0.62
  3. Venu Gopal Pillarisetty · 3 shared papers, 2021–2023 · strength 0.51
  4. Rachael Ann Safyan · 2 shared papers, 2023–2026 · strength 0.45
  5. Martin C. Whittle · 1 shared paper, 2026 · strength 0.23
  6. Andrew Eugene Hendifar · 1 shared paper, 2026 · strength 0.23
  7. Ben George · 1 shared paper, 2026 · strength 0.23
  8. Sita Kugel · 1 shared paper, 2026 · strength 0.23
  9. Tomislav Dragovich · 1 shared paper, 2026 · strength 0.23
  10. Sunil R. Hingorani · 1 shared paper, 2026 · strength 0.23
  11. Howard S. Höchster · 1 shared paper, 2026 · strength 0.23
  12. Gustavo Cartaxo de Lima Gössling · 1 shared paper, 2022 · strength 0.22
  13. Diane M. Simeone · 2 shared papers, 2016–2021 · strength 0.19
  14. Vaibhav Sahai · 2 shared papers, 2016–2021 · strength 0.19
  15. Peter James O'Dwyer · 1 shared paper, 2023 · strength 0.16
  16. Daneng Li · 1 shared paper, 2023 · strength 0.16
  17. Efrat Dotan · 1 shared paper, 2023 · strength 0.16
  18. Gentry G. King · 1 shared paper, 2023 · strength 0.16
  19. Jonathan G. Sham · 1 shared paper, 2023 · strength 0.16
  20. Sam H. Whiting · 1 shared paper, 2023 · strength 0.16
  21. Robert W. Cowan · 1 shared paper, 2021 · strength 0.13
  22. Erica D. Pratt · 1 shared paper, 2021 · strength 0.13
  23. Valerie Gunchick · 1 shared paper, 2021 · strength 0.13
  24. Andrew D. Rhim · 1 shared paper, 2021 · strength 0.13
  25. Deepti Reddi · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.